Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Glipizide). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Diaplus XR 10 is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Like any other oral hypoglycaemic agent, dosage of Glipizide is not fixed and may be adjusted through periodic monitoring of blood glucose level. Short term administration of Glipizide may be sufficient during periods of transient loss of control of blood glucose in patients, usually controlled well on diet.In general, Glipizide should be given approximately 30 minutes before a meal to achieve the maximum reduction in postprandial hyperglycaemia. Initial dose: The recommended starting dose is 5 mg, given before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg. Dosage adjustments: Dosage adjustment may be done at intervals of several days by an increment of 2.5-5 mg, as determined by blood glucose response. If response to a single dose is not satisfactory, dividing that dose might prove effective. The maximum recommended once daily dose is 15 mg. Doses above 15 mg should ordinarily be divided and given before meals of adequate calorie content. The maximum recommended total daily dose is 40 mg. Maintenance: Some patients may be effectively controlled on a once daily regimen, while others show better response with divided dosing. Total daily dose above 30 mg have been safely given on bid basis to long term patients. Patients can usually be stabilized on a dosage ranging from 2.5 to 30 mg daily. In elderly, debilitated or malnourished patients, and patients with impaired renal or hepatic function: The initial and maintenance dosing should be conservative to avoid hypoglycaemic reactions.Patients receiving insulin: Many stable non-insulin-dependent diabetic patients receiving Insulin may be safely placed on Glipizide if the physician decides to do so.Patients receiving other oral hypoglycaemic agents: As with other sulphonylurea, no transition period is necessary while transferring patients to Glipizide. Patients should be observed carefully for any possible hypoglycaemic effect due to overlapping of drug effects.Pediatric Use: Safety and effectiveness in children have not been established.
Side Effects
Diapizi's side effects are generally dose related, temporary, and tend to improve when the dose is lowered or the medicine is stopped. Gastrointestinal effects: Complaints such as nausea, diarrhoea, constipation and stomach pain have been reported. These are usually dose related and tend to go away once the dose is split up or reduced. Cholestatic jaundice can occur rarely with drugs of this kind, and Diapizi should be stopped if this happens. Dermatological effects: Allergic skin reactions, including redness, measles like or raised red rash, hives, itching and eczema, have been reported. These often clear up as treatment continues. If they do not, the medicine should be stopped. Haematologic effects: Low white blood cell count, agranulocytosis, low platelet count, haemolytic anaemia, aplastic anaemia and pancytopenia have been reported with sulphonylureas. Metabolic effects: Hepatic porphyria and disulphiram like reactions have been reported with sulphonylureas. Endocrine effects: Low blood sodium and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) have been reported with this and other sulphonylureas. Miscellaneous effects: Dizziness, drowsiness and headache have been reported in people treated with Diapizi. These are usually temporary and rarely require treatment to be stopped.
Cautions & Contraindications
Warnings & Precautions
Hypoglycaemia: All sulphonylurea drugs, including Diapizi, are capable of causing severe hypoglycaemia. Careful patient selection, correct dosing and clear instructions all help avoid hypoglycaemic episodes. In patients with renal or hepatic insufficiency, blood levels of Diapizi may rise, and the drug's gluconeogenic capacity may be reduced; both effects increase the risk of serious hypoglycaemic reactions. Elderly, debilitated or malnourished patients, as well as those with adrenal or pituitary insufficiency, are especially vulnerable to the glucose lowering effects of this drug. Patients should be advised to eat meals regularly and to avoid exercising excessively without taking in additional calories. Renal and hepatic disease: In patients with impaired renal or hepatic function, the metabolism and excretion of Diapizi may be slowed, which can lead to prolonged hypoglycaemia. Appropriate measures should be taken in such cases. Loss of blood glucose control: When a patient who is stable on an antidiabetic regimen is exposed to stress, such as fever, trauma, infection or surgery, control of blood glucose may be lost. In this situation, it may become necessary to stop Diapizi and start insulin instead. The effectiveness of any oral hypoglycaemic drug, including Diapizi, in lowering blood glucose to the desired level tends to decline in many patients over time. This may result from secondary failure, meaning either progression in the severity of the diabetes itself or a reduced response to the drug.
Contraindications
Glipizide should not be used by anyone who is hypersensitive to it or to any component of the product. It is also unsuitable for juvenile-onset diabetes and for severe or unstable "brittle" diabetes, or for diabetes complicated by ketosis and acidosis, major surgery, severe sepsis, or severe trauma. It should likewise be avoided in patients with severe renal, hepatic, or thyroid impairment, or with coexistent renal and hepatic disease.